Please login to the form below

Not currently logged in
Email:
Password:

RRMS

This page shows the latest RRMS news and features for those working in and with pharma, biotech and healthcare.

Novartis expands its generics franchise with natalizumab biosimilar

Novartis expands its generics franchise with natalizumab biosimilar

The drug is currently in phase 3 clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS).

Latest news

More from news
Approximately 8 fully matching, plus 30 partially matching documents found.

Latest from PMHub

  • Innovative approaches in the treatment of multiple sclerosis

    THE TWO TYPES OF MS. There are two main clinical presentations of MS – Relapsing Refractory MS (RRMS) and Progressive MS (PMS). ... In RRMS symptoms are intermittent but relapses gradually become more frequent, severe and longer-lasting as the disease

  • Innovative approaches in the treatment of multiple sclerosis

    THE TWO TYPES OF MS. There are two main clinical presentations of MS – Relapsing Refractory MS (RRMS) and Progressive MS (PMS). ... In RRMS symptoms are intermittent but relapses gradually become more frequent, severe and longer-lasting as the disease

  • It's time to change the conversation

    Take Multiple Sclerosis (MS) for example. MS has four different disease manifestations: Relapsing Remitting (RRMS), Secondary Progressive (SPMS), Primary Progressive (PPMS) and Progressive Relapsing (PRMS). ... Today however, given the research and the

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics